- Home
- TBPH vs VMO Comparison
TBPH vs VMO Comparison
Compare TBPH & VMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- VMO
- Stock Information
- Founded
- TBPH 2013
- VMO 1992
- Country
- TBPH United States
- VMO United States
- Employees
- TBPH N/A
- VMO N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- VMO Trusts Except Educational Religious and Charitable
- Sector
- TBPH Health Care
- VMO Finance
- Exchange
- TBPH Nasdaq
- VMO Nasdaq
- Market Cap
- TBPH 536.5M
- VMO 611.0M
- IPO Year
- TBPH N/A
- VMO N/A
- Fundamental
- Price
- TBPH $11.15
- VMO $9.33
- Analyst Decision
- TBPH Strong Buy
- VMO
- Analyst Count
- TBPH 5
- VMO 0
- Target Price
- TBPH $16.60
- VMO N/A
- AVG Volume (30 Days)
- TBPH 245.1K
- VMO 254.7K
- Earning Date
- TBPH 08-04-2025
- VMO 01-01-0001
- Dividend Yield
- TBPH N/A
- VMO 4.39%
- EPS Growth
- TBPH N/A
- VMO N/A
- EPS
- TBPH N/A
- VMO N/A
- Revenue
- TBPH $65,266,000.00
- VMO N/A
- Revenue This Year
- TBPH $43.18
- VMO N/A
- Revenue Next Year
- TBPH N/A
- VMO N/A
- P/E Ratio
- TBPH N/A
- VMO N/A
- Revenue Growth
- TBPH 6.11
- VMO N/A
- 52 Week Low
- TBPH $7.44
- VMO $7.86
- 52 Week High
- TBPH $11.82
- VMO $9.87
- Technical
- Relative Strength Index (RSI)
- TBPH 62.38
- VMO 65.47
- Support Level
- TBPH $10.87
- VMO $9.03
- Resistance Level
- TBPH $11.44
- VMO $9.10
- Average True Range (ATR)
- TBPH 0.29
- VMO 0.07
- MACD
- TBPH -0.00
- VMO 0.04
- Stochastic Oscillator
- TBPH 71.92
- VMO 100.00
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.